ERBB2 and non-small cell lung carcinoma: A follow-up phase II DESTINY-Lung02 trial evaluated T-DXd 5.4 mg/kg every 3 weeks compared to 6.4 mg/kg every 3 weeks in previously treated HER2-mutant metastatic NSCLC [130].